22:55 , Jun 22, 2018 |  BC Extra  |  Preclinical News

Blocking LSD1 could activate cancer immune response via HERV

A Harvard Medical School team led by immunology and pathology professor Arlene Sharpe has shown inhibiting lysine-specific demethylase (LSD1; KDM1A) increases human endogenous retrovirus (HERV) transcription to activate an immune response that could help treat...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
19:58 , Sep 21, 2017 |  BC Innovations  |  Tools & Techniques

On your marks

With less fanfare than the first two waves, a quiet rise in activity is driving a revival of interest in epigenetics, despite little progress in solving the fundamental challenges that have dogged the field from...
18:50 , Jul 21, 2017 |  BC Week In Review  |  Company News

Roche ends cancer deal with Oryzon

Roche (SIX:ROG; OTCQX:RHHBY) terminated a 2014 deal with Oryzon Genomics S.A. (Madrid:ORY) granting the pharma rights to cancer candidate ORY-1001. Oryzon said Roche's decision was part of a portfolio reprioritization. Roche is responsible for completing an...
23:40 , Jul 20, 2017 |  BC Extra  |  Company News

Roche ends cancer deal with Oryzon

Oryzon Genomics S.A. (Madrid:ORY) fell €0.80 (27%) to €2.11 on Thursday after Roche (SIX:ROG;OTCQX:RHHBY) terminated a 2014 deal granting the pharma rights to cancer candidate ORY-1001. Oryzon said Roche's decision was part of a portfolio...
18:11 , Jun 16, 2017 |  BioCentury  |  Product Development

Everywhere IDO

Incyte Corp. and partner Merck & Co. Inc. now have reported the data that led them to plan Phase III trials that combine their molecules in five cancer indications. For Incyte, the next step is...
23:20 , Nov 10, 2016 |  BC Week In Review  |  Clinical News

IMG-7289: Ph I/II started

Imago began an open-label, Australian Phase I/II trial to evaluate oral IMG-7289 with and without tretinoin in 30 patients. The dose-escalation Phase I portion will identify the selected dose of IMG-7289 for the dose-expansion Phase...
07:00 , Aug 22, 2016 |  BC Week In Review  |  Company News

Rasna, Active With Me deal

Rasna reverse-merged with Active With Me. The combined company retained Rasna’s name and will focus on modulating nucleophosmin ( NPM1; B23) and lysine-specific demethylase 1 ( LSD1; KDM1A), which it says is...
07:00 , Aug 11, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Glycogen synthase kinase 3β (GSK3B); ubiquitin specific peptidase 22 (USP22); lysine-specific demethylase 1 (LSD1; KDM1A)

Cancer INDICATION: Brain cancer Patient sample and mouse studies suggest that inhibiting the GSK3β-USP22-LSD1 axis could help treat glioblastoma multiforme (GBM) and other brain cancers. In tumor samples from GBM and astrocytoma patients, levels of GSK3β, USP22...
07:00 , May 30, 2016 |  BC Week In Review  |  Company News

Oryzon, Roche deal

Oryzon and Roche extended by one year until March 2017 a collaborative research program to explore the potential of ORY-1001 in cancer and hematology indications beyond acute leukemia. The research program was included as...